ID

37018

Beskrivning

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS); ODM derived from: https://clinicaltrials.gov/show/NCT02428218

Länk

https://clinicaltrials.gov/show/NCT02428218

Nyckelord

Versioner (1)
  1. 2019-06-30 2019-06-30 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

30 juni 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Relapsing-Remitting Multiple Sclerosis NCT02428218

Engelsk

Eligibility Relapsing-Remitting Multiple Sclerosis NCT02428218

1 Formulär  
Criteria
Beskrivning

Criteria

informed consent and assent as appropriate
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
must have a body weight of ≥30 kg
Beskrivning

Body Weight

Datatyp

boolean

Alias
UMLS CUI [1]
C0005910
must have a diagnosis of rrms as defined by the revised consensus definition for pediatric multiple sclerosis (ms)
Beskrivning

Multiple Sclerosis, Relapsing-Remitting

Datatyp

boolean

Alias
UMLS CUI [1]
C0751967
must be ambulatory with a converted krutzke baseline expanded disability status scale (edss) score between 0 and 5.0, inclusive
Beskrivning

Ambulatory | EDSS

Datatyp

boolean

Alias
UMLS CUI [1]
C0439841
UMLS CUI [2]
C0451246
key exclusion criteria:
Beskrivning

Exclusion Criteria Main

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
primary progressive, secondary progressive, or progressive relapsing ms.
Beskrivning

Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Progressive Relapsing

Datatyp

boolean

Alias
UMLS CUI [1]
C0751964
UMLS CUI [2]
C0751965
UMLS CUI [3]
C0393666
history of disorders mimicking ms, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., sjögren disease and lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
Beskrivning

Demyelinating Diseases | Encephalomyelitis, Acute Disseminated | Systemic autoimmune disease | Sjogren's Syndrome | Lupus Erythematosus | Metabolic Diseases | Dystrophy | Communicable Diseases

Datatyp

boolean

Alias
UMLS CUI [1]
C0011303
UMLS CUI [2]
C0014059
UMLS CUI [3]
C2895206
UMLS CUI [4]
C1527336
UMLS CUI [5]
C0409974
UMLS CUI [6]
C0025517
UMLS CUI [7]
C0333606
UMLS CUI [8]
C0009450
history of severe allergic or anaphylactic reactions, or known drug hypersensitivity to dimethyl fumarate (dmf) or fumaric acid esters.
Beskrivning

Allergic Reactions Severe | Anaphylaxis Severe | Hypersensitivity Dimethyl fumarate | Hypersensitivity Fumaric Acid Esters

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0002792
UMLS CUI [2,2]
C0205082
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0058218
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C1959568
prior treatment with any of the following medications within 12 months prior to randomization: mitoxantrone, cyclophosphamide, rituximab.
Beskrivning

Mitoxantrone | Cyclophosphamide | rituximab

Datatyp

boolean

Alias
UMLS CUI [1]
C0026259
UMLS CUI [2]
C0010583
UMLS CUI [3]
C0393022
prior treatment with any of the following medications or procedures within 6 months prior to randomization: fingolimod, teriflunomide, natalizumab, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, laquinimod, intravenous (iv) immunoglobulin, plasmapheresis or cytapheresis.
Beskrivning

fingolimod | teriflunomide | natalizumab | Cyclosporine | Azathioprine | Methotrexate | mycophenolate mofetil | laquinimod | Immunoglobulins, Intravenous | Plasmapheresis | Cytapheresis

Datatyp

boolean

Alias
UMLS CUI [1]
C1699926
UMLS CUI [2]
C1718383
UMLS CUI [3]
C1172734
UMLS CUI [4]
C0010592
UMLS CUI [5]
C0004482
UMLS CUI [6]
C0025677
UMLS CUI [7]
C0209368
UMLS CUI [8]
C1260208
UMLS CUI [9]
C0085297
UMLS CUI [10]
C0032134
UMLS CUI [11]
C0079186
note: other protocol defined inclusion/exclusion criteria may apply.
Beskrivning

Eligibility Criteria Study Protocol

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Tillbaka till toppen

Similar models

Eligibility Relapsing-Remitting Multiple Sclerosis NCT02428218

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Informed Consent
Item
informed consent and assent as appropriate
boolean
C0021430 (UMLS CUI [1])
Body Weight
Item
must have a body weight of ≥30 kg
boolean
C0005910 (UMLS CUI [1])
Multiple Sclerosis, Relapsing-Remitting
Item
must have a diagnosis of rrms as defined by the revised consensus definition for pediatric multiple sclerosis (ms)
boolean
C0751967 (UMLS CUI [1])
Ambulatory | EDSS
Item
must be ambulatory with a converted krutzke baseline expanded disability status scale (edss) score between 0 and 5.0, inclusive
boolean
C0439841 (UMLS CUI [1])
C0451246 (UMLS CUI [2])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Progressive Relapsing
Item
primary progressive, secondary progressive, or progressive relapsing ms.
boolean
C0751964 (UMLS CUI [1])
C0751965 (UMLS CUI [2])
C0393666 (UMLS CUI [3])
Demyelinating Diseases | Encephalomyelitis, Acute Disseminated | Systemic autoimmune disease | Sjogren's Syndrome | Lupus Erythematosus | Metabolic Diseases | Dystrophy | Communicable Diseases
Item
history of disorders mimicking ms, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., sjögren disease and lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
boolean
C0011303 (UMLS CUI [1])
C0014059 (UMLS CUI [2])
C2895206 (UMLS CUI [3])
C1527336 (UMLS CUI [4])
C0409974 (UMLS CUI [5])
C0025517 (UMLS CUI [6])
C0333606 (UMLS CUI [7])
C0009450 (UMLS CUI [8])
Allergic Reactions Severe | Anaphylaxis Severe | Hypersensitivity Dimethyl fumarate | Hypersensitivity Fumaric Acid Esters
Item
history of severe allergic or anaphylactic reactions, or known drug hypersensitivity to dimethyl fumarate (dmf) or fumaric acid esters.
boolean
C1527304 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0058218 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C1959568 (UMLS CUI [4,2])
Mitoxantrone | Cyclophosphamide | rituximab
Item
prior treatment with any of the following medications within 12 months prior to randomization: mitoxantrone, cyclophosphamide, rituximab.
boolean
C0026259 (UMLS CUI [1])
C0010583 (UMLS CUI [2])
C0393022 (UMLS CUI [3])
fingolimod | teriflunomide | natalizumab | Cyclosporine | Azathioprine | Methotrexate | mycophenolate mofetil | laquinimod | Immunoglobulins, Intravenous | Plasmapheresis | Cytapheresis
Item
prior treatment with any of the following medications or procedures within 6 months prior to randomization: fingolimod, teriflunomide, natalizumab, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, laquinimod, intravenous (iv) immunoglobulin, plasmapheresis or cytapheresis.
boolean
C1699926 (UMLS CUI [1])
C1718383 (UMLS CUI [2])
C1172734 (UMLS CUI [3])
C0010592 (UMLS CUI [4])
C0004482 (UMLS CUI [5])
C0025677 (UMLS CUI [6])
C0209368 (UMLS CUI [7])
C1260208 (UMLS CUI [8])
C0085297 (UMLS CUI [9])
C0032134 (UMLS CUI [10])
C0079186 (UMLS CUI [11])
Eligibility Criteria Study Protocol
Item
note: other protocol defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial